NovaBay wins US patent for new antimicrobial compounds

NovaBay has recently filed additional patent applications including ones for compositions of matter of additional Aganocide compounds, methods of use and formulations, and is preparing further applications in other areas. Similar patent filings have been made in all major international countries that have significant pharmaceutical markets.

The Aganocide compounds are novel N-chlorinated antimicrobial molecules developed by NovaBay. They are designed to mimic the antimicrobial action of small molecules produced naturally by white blood cells. In laboratory testing, the Aganocide molecules maintain the efficacy and safety of the natural molecules but are more stable, enabling their potential use as potent antimicrobial products, the company said.

Lawrence Rozsnyai, director of intellectual property and licensing at NovaBay, said: “We are continuing to secure and expand our proprietary position in the Aganocide compounds and related antimicrobial technologies. The issuance of this patent, the first one issued for the Aganocide compounds, significantly strengthens our patent portfolio, and represents a valuable asset for both NovaBay and its partners.”